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Differential genomic imprinting regulates paracrine
and autocrine roles of IGF2 in mouse adult
neurogenesis
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M. Constancia3,4,5, A. Ward6, T.R. Menheniott7 & A.C. Ferguson-Smith2,4
Genomic imprinting is implicated in the control of gene dosage in neurogenic niches. Here we
address the importance of Igf2 imprinting for murine adult neurogenesis in the subventricular
zone (SVZ) and in the subgranular zone (SGZ) of the hippocampus in vivo. In the SVZ,
paracrine IGF2 is a cerebrospinal ﬂuid and endothelial-derived neurogenic factor requiring
biallelic expression, with mutants having reduced activation of the stem cell pool and
impaired olfactory bulb neurogenesis. In contrast, Igf2 is imprinted in the hippocampus acting
as an autocrine factor expressed in neural stem cells (NSCs) solely from the paternal allele.
Conditional mutagenesis of Igf2 in blood vessels conﬁrms that endothelial-derived IGF2
contributes to NSC maintenance in SVZ but not in the SGZ, and that this is regulated by the
biallelic expression of IGF2 in the vascular compartment. Our ﬁndings indicate that a
regulatory decision to imprint or not is a functionally important mechanism of transcriptional
dosage control in adult neurogenesis.
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S
tem cells are characterized by self-renewal and multi-
potency, and the stem cell niche is the functional
microenvironment that enables their continuous self-
renewal in response to physiological or pathological challenges1.
Elucidating the components and regulation of the niche is
important to understand disease processes and the development
of future regenerative therapies. A number of factors regulate
neural stem cell (NSC) function in these niches, including
cytoarchitectural arrangement, extracellular matrix components,
autocrine, paracrine and vascular factors2,3. The adult neurogenic
niches consist of a complex collection of neural precursors,
neuroblasts, glial cells and angioblasts in close proximity to small
capillaries4,5. Neurogenesis occurs normally in the adult brain in
two locations: the subventricular zone (SVZ) in the walls of the
lateral ventricles (LVs)6 and the subgranular zone (SGZ) in the
dentate gyrus (DG) of the hippocampus7. Neurons originating
from the SVZ migrate to the olfactory bulb (OB) via the rostral
migratory stream to generate new or replacement neurons8,
whereas hippocampal neurogenesis is thought to play a role in
learning and memory9,10. NSCs in the SVZ are glial ﬁbrillary
acidic protein (GFAP)-expressing radial glia-like cells6 that
contact the LV apically, forming a pinwheel conﬁguration
surrounded by ependymal cells11. They extend long basal
processes that contact blood vessels through specialized end-
feet5. In the SGZ, NSCs also resemble astrocytes and extend
a single radial process towards the molecular layer. A
morphologically distinct class of progenitor cells that has
horizontal processes has also been identiﬁed in the SGZ. The
horizontal and radial progenitors have different proliferation
rates and respond differently to neurogenic stimuli12, suggesting
that in the SGZ there are different populations of progenitors
with different properties. Dividing stem cells in the SGZ are also
in close proximity to an extensive network of interconnected
blood vessels and parenchymal astrocytes that can regulate their
proliferation and differentiation via paracrine signalling4. This
coupling of neurogenesis with angiogenesis, together with the
close anatomical proximity of the SVZ and SGZ to blood vessels
suggests a role for instructive vascular signalling in the regulation
of NSC proliferation and/or differentiation5,13.
The ventricles contain cerebrospinal ﬂuid (CSF) enriched with
proteins secreted by the choroid plexus (CP) and brain
vasculature. Many of these blood vessel and CSF-derived
molecules are known to regulate progenitor cell proliferation
during embryonic brain development, including ﬁbroblast growth
factors (FGFs), sonic hedgehog, bone morphogenic proteins,
retinoic acid, Wnts and insulin-like growth factors (IGFs)14,15.
Molecules in the CSF also inﬂuence adult neurogenesis in the
SVZ as they bind to the primary cilia of adjacent SVZ progenitor
cells, which extend into the ventricular space14,16. In contrast,
neurogenesis in the DG may be less affected by CSF constituents.
For example, intra-cerebroventricular infusion of exogenous
epidermal growth factor and FGF2 expanded the SVZ
precursor population, while no effect was seen in the more
distant hippocampus17.
IGFs (IGF1 and IGF2) are mitogenic polypeptides with
structural homology to pro-insulin; they signal predominantly
via the IGF type-1 receptor (IGF1R) in the order of afﬁnity
IGF14IGF24insulin18. IGF2 also binds to the IGF type-2
receptor (IGF2R), which acts as a sink for excess IGF2 removal
via internalization and lysosomal degradation19. IGF2 is well
established as a critical factor regulating cell proliferation, growth,
differentiation and survival. While fetal IGF2 is abundant, its
concentration diminishes postnatally when growth-hormone-
dependent IGF1 signalling dominates20,21. In humans, altered
IGF2 dosage results in prenatal growth disorders and
developmental defects22. However, in adults the expression of
IGF2 is predominantly restricted to the brain where its function
in vivo is poorly understood20,23. Lately, the hypothesis that the
IGF system has a role in neurogenesis has gathered support24–26.
IGF1, signalling through the IGF1R, is thought to inﬂuence
embryonic brain growth and weight by reducing apoptosis and
shortening the G1 cell-cycle stage in progenitor cells27,28.
Furthermore, the CSF has been shown to have an age-
dependent effect on embryonic cortical neural progenitor
proliferation attributed to CP-secreted IGF2 (ref. 14). More
recently, a functional role for IGF2 has been shown in memory29,
where it is thought to act by increasing the survival of adult-born
hippocampal neurons30. In addition, autocrine IGF2 seems to be
crucial for maintaining NSC proliferation in the adult DG and
promotes stemness of neural restricted precursors24,31. IGF2 has
also been suggested to inﬂuence the adult brain under
pathological conditions, as the uncontrolled proliferation that is
characteristic of glioblastoma has been linked to elevated CSF–
IGF2 concentration32. Together these studies implicate IGF2 as
an important neurogenic regulator both during in utero
development and in adult life.
Genomic imprinting is a process that causes genes to be
expressed according to their parental origin, resulting in
activation of one of the two alleles of a gene and repression of
the other. In most human and mouse tissues, Igf2 is expressed
only from the paternally inherited chromosome23,33,34. However,
it is speciﬁcally biallelically expressed (that is, from both the
maternal and paternal chromosomes) in embryonic and postnatal
human and mouse CP epithelium and leptomeninges23,35.
Imprinting at the Igf2 locus is mediated by the recruitment of
the CCCTC-binding factor (CTCF) to the unmethylated maternal
differentially methylated domain (DMD) restricting access of
downstream enhancers to the Igf2 gene promoters, thus
preventing expression of the maternal allele36,37. However,
biallelic expression of Igf2 in the CP is regulated independently
of the DMD, via a centrally conserved domain enhancer region35
located 50 of the DMD and hence outside its inﬂuence. Nothing is
known about the imprinting status of Igf2 in the adult neurogenic
niches.
We recently found that selective biallelic expression of another
paternally expressed imprinted gene, Dlk1, in the SVZ is required
for normal postnatal neurogenesis38, suggesting that selective
brain-speciﬁc modulation of imprinting at other loci, such as Igf2,
may also have a signiﬁcant role in neurogenesis. Here, we
consider the role of imprinting in the dosage control of Igf2 and
its relevance for the function of IGF2 as a neurogenic regulator. In
this study, we demonstrate that the physiological absence of
imprinting through the speciﬁc activation of the maternal Igf2
allele in the brain vasculature and the CSF system, resulting in
biallelic expression, is required for adult SVZ neurogenesis. In
contrast, in the SGZ of the hippocampus where there is an
autocrine requirement for lower levels of IGF2, its expression is
monoallelic and in Igf2 mutants, neurogenesis is perturbed only
after deletion of the paternal allele. Our ﬁndings uncover the
importance of genomic imprinting in the spatial and temporal
dosage control of IGF2 acting through speciﬁc mechanisms to
regulate the different neurogenic niches of the adult brain.
Results
Paternal and maternal expression of Igf2 control brain growth.
To characterize the functional role of Igf2 imprinting in neuro-
genesis, we used a murine genetic model where the Igf2 gene
between exons 4 and 6 is replaced with a promoterless
IRES:lacZneo cassette39. First, we conﬁrmed the previously
reported neonatal growth phenotypes upon paternal (Igf2þ /pat)
and maternal (Igf2mat/þ ) transmission of the mutation and in
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homozygous (Igf2mat/pat) mutant mice. As expected, body and
brain weights were reduced in Igf2þ /pat mice at birth (postnatal
day 0), while that of Igf2mat/þ mice was similar to their wild-type
littermates, conﬁrming that imprinted Igf2 expressed from the
paternal allele is important for prenatal somatic and cerebral
growth (Fig. 1a; Supplementary Fig. 1). In contrast, in the adult,
brain weights were reduced both in Igf2þ /pat and Igf2mat/þ
animals, and further reduced in the Igf2 homozygous mutant
(Fig. 1a; Supplementary Fig. 1), indicating that biallelically
expressed Igf2 might control the growth of the developing brain
speciﬁcally during the postnatal period.
We next assessed the cellular distribution and allelic expression
of IGF2 in the adult brain, as this has not been described in detail.
Analysis of Igf2 expression by b-galactosidase staining in the
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Figure 1 | Paternal and maternal expression of Igf2 differentially controls brain weights. (a) Brain weights in grams (g) of postnatal day 0 and adult
(2 months old) wild-type (Igf2þ /þ ), maternal (Igf2mat/þ ) and paternal (Igf2þ /pat) heterozygous and homozygous knockout (Igf2mat/pat) mice.
(b) Immunohistochemistry for b-galactosidase (red), Ki67 (pink) and GFAP (green) in the SVZ of homozygous knockout Igf2mat/pat mice.
(c) Immunohistochemistry for IGF2 within the SVZ of wild-type mice (left panel). Immunohistochemistry for IGF2 (red), GFAP (green) and SOX2 (blue)
in the SVZ of wild-type mice. White arrowheads denote speciﬁc IGF2 staining in type-B NSC cells (right panel). (d) Immunohistochemistry for
b-galactosidase (red) and GFAP (green) in the hippocampus of wild-type, maternal and paternal transmission heterozygote mice, showing expression only
from the paternal allele. (e) Immunohistochemistry for IGF2 (red) and GFAP (green) within the hippocampus of Igf2þ /þ , Igf2mat/þ and Igf2þ /pat mice
showing that Igf2 is imprinted. DAPI was used to counterstain nuclei. vl, ventricle lumen. One-way analysis of variance and Tukey’s post-test. P values and
number of animals per genotype or tissue samples are indicated. All error bars show s.e.m. Scale bars, 20mm (b,c); 70mm (d) (high-magniﬁcation images:
7 mm); 30mm (e) (high-magniﬁcation images 7mm). DAPI, 4,6-diamidino-2-phenylindole.
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forebrain of adult mice conﬁrmed LacZ expression in the
meninges, leptomeninges and CP epithelium in both Igf2þ /pat
and Igf2mat/þ , as previously described for the embryo
(Supplementary Fig. 2a–e). To determine the cellular distribution
of IGF2 expression at the protein level in vivo, immunostaining of
IGF2 in combination with GFAP was performed on maternal and
paternal heterozygote adult brains. IGF2 staining was observed in
blood vessels of both Igf2þ /pat and Igf2mat/þ heterozygotes,
revealing a previously undescribed biallelic expression of Igf2 in
the vasculature of both the developing and adult brain
(Supplementary Fig. 3c). IGF2 expression from both parental
chromosomes was also observed in meninges and CP
(Supplementary Fig. 3a–c). This was conﬁrmed by assessing
Igf2 imprinting status in tissues of wild-type F1-hybrid offspring
from reciprocal crosses of Mus musculus domesticus (C57BL6/J)
and Mus musculus castaneus (CAST/EiJ) strains (Supplementary
Fig. 3d,e). Placental samples from reciprocal hybrids showed the
expected paternally inherited imprinted expression of Igf2;
however, meninges and CP from adult mice showed biallelic
(non-imprinted) expression of the gene (Supplementary Fig. 3e).
The strength of this murine model is that combined analysis of
b-galactosidase and IGF2 protein expression allows for the
coincident delineation of IGF2 transcript and protein localization.
We therefore analysed Igf2 expression by performing
b-galactosidase staining in Igf2mat/pat mice, which showed no
transcription of the gene in the SVZ (Fig. 1b); however, IGF2
protein could be readily detected by immunohistochemistry in
the SVZ, both in the ependymal cells lining the ventricle and in
GFAPþ type-B1 subependymal cells (Fig. 1c; Supplementary
Fig. 4a). Importantly, in the SVZ we could detect cytoplasmic
IGF2 in all of the GFAPþ /Sox2þ cells in the absence of
Igf2/b-gal expression (Fig. 1c), indicating cellular uptake of the
protein from an exogenous source. In contrast, in the SGZ,
b-galactosidase staining of adult maternal and paternal transmis-
sion heterozygous mice showed that endogenous Igf2 is produced
from the paternal allele in this niche (Supplementary Fig. 4b).
These data were conﬁrmed by in vivo immunostaining for
the presence of b-galactosidase in combination with GFAP,
demonstrating transcription of endogenous Igf2 in the GFAPþ
population in the hippocampus of the Igf2þ /pat mice (Fig. 1d).
Consistently, IGF2 protein was also observed only from the
paternal allele in the GFAPþ stem cell population of the DG
(Fig. 1e; Supplementary Fig. 4c), indicating that in this niche
canonically imprinted IGF2 functions in an autocrine manner.
Igf2 differential imprinting regulates SVZ and SGZ neurogenesis.
To investigate the role of Igf2 imprinting in the neurogenic niches
in vivo, we analysed the SVZ and SGZ of wild-type Igf2þ /pat or
Igf2mat/þ mice39. Igf2 homozygous null animals were also
analysed. Two-month-old mice were injected with the
nucleotide analogue CldU 3 weeks before killing (Fig. 2a). In
the SVZ, fast-proliferating transit-amplifying progenitors dilute
out the CldU, which is only retained in slowly proliferating NSCs
(label-retaining cells, LRCs) and OB newborn neurons that ceased
to divide and terminally differentiated soon after the injection40.
Igf2 heterozygous mice showed a speciﬁc reduction in the
proportion of GFAPþ /SOX2þ and GFAPþ /Nestin CldU-
LRCs that was less proliferative as measured by the cell-cycle
antigen Ki67 (Fig. 2b,c; Supplementary Fig. 5a–c), suggesting that
IGF2 regulates the cycling of activated B cells. Consistent with
this, a reduced number of type-B1 NSC g-tubulinþ apical
contacts in the anterior medial wall of the LV11 were evident in
both maternal and paternal Igf2 heterozygous mice (Fig. 2d,e).
Importantly, Igf2 homozygous mutants showed a more
severe decrease in the number of CldU-LRCs, indicating a
dosage-dependent mitogenic effect of Igf2 on NSC proliferation
(Fig. 2b–d). As a consequence of the reduced number of NSCs in
the Igf2 mutant SVZs, we found a reduction in the percentage of
MASH1þ transient amplifying progenitors and of the DCXþ
neuroblast population (Supplementary Fig. 5d). This resulted in
fewer newborn neurons reaching the OB, visualized by a highly
signiﬁcant decrease in the numbers of postmitotic CldUþ newly
formed neurons in the granular and periglomerular layers of the
mutant OBs (Fig. 2f; Supplementary Fig. 5e). In agreement with
this, the number of primary neurospheres obtained ex vivo was
also reduced, regardless of the parental origin of the mutation
(Supplementary Fig. 5f,g), supporting a role for IGF2 derived
from both parental chromosomes in regulating the number and
cycling of activated NSCs within the SVZ.
In the DG of the SGZ, two major classes of cells were expected
to retain CldU labelling: slowly dividing GFAP/SOX2þ NSCs
that do not dilute the CldU through divisions (LRCs) and
newborn neurons that incorporated CldU in the granular layer
before cell-cycle exit. Quantiﬁcation of the LRCs in the DG
showed that the number of GFAPþ /Sox2þ /LRC cells in the
SGZ was signiﬁcantly reduced in the paternal heterozygous and
homozygous knockout Igf2 mice (Fig. 2g), combined with a
speciﬁc proliferation defect in GFAPþ cells as measured by Ki67
labelling (Fig. 2h). Strikingly, no differences in the maternal
heterozygous compared with wild-type SGZ were found
(Fig. 2g,h), consistent with Igf2 imprinting in the SGZ. As a
consequence of the fewer NSCs in the paternal heterozygotes and
homozygous mutant mice, we found a reduction in the
percentage of the DCXþ neuroblast population (Fig. 2h)
resulting in reduced neurogenesis as visualized by a signiﬁcant
decrease in the number of postmitotic NeuNþ /LRC newly
formed neurons in the granular layer of the mutant hippocampus
(Fig. 2i). Supporting the in vivo data, the number of ex vivo
primary neurospheres obtained from the SGZ was reduced in
the paternal heterozygotes and homozygous mutant mice,
whereas no changes were found in the maternal heterozygotes
(Supplementary Fig. 5f,g). This parental-origin-dependent
decrease in the number of stem cells and their proliferation rate
in the SGZ in Igf2 mutant mice indicate that, in contrast to the
SVZ, canonically imprinted, paternally expressed autocrine Igf2
plays an important function in regulating adult hippocampal
neurogenesis in vivo.
Paracrine and autocrine IGF2 regulate SVZ- and SGZ-derived
NSCs. On the basis of IGF2 in vivo localization, we hypothesized
that IGF2 is biallelically produced from the neurogenic niche
promoting self-renewal and proliferation of SVZ NSCs in a
paracrine manner and monoallelically expressed in the hippo-
campus of SGZ NSCs in an autocrine manner. NSCs located in
speciﬁc neurogenic niches proliferate and self-renew in close
apposition to capillaries, and some endothelial-derived molecules
have been shown to regulate NSC behaviour4,5,13,16. Indeed, our
data indicate that although adult SVZ NSCs do not produce
endogenous IGF2, they may take up the factor from the blood
vessels and/or the CSF, two IGF2-expressing compartments in
direct contact with the adult stem cells (Fig. 3a). However, NSCs
from the SGZ that produce endogenous IGF2 may not be equally
inﬂuenced by niche-secreted IGF2. To further test this hypothesis,
we isolated NSCs from wild-type adult SVZ and SGZ and grew
them in vitro as ﬂoating neurospheres40. In agreement with the
in vivo expression data, SVZ neurosphere cultures did not express
Igf2 (Fig. 3b). However, as previously described14,31, addition of
recombinant IGF2 protein to insulin-free neurosphere cultures
resulted in 70% more neurospheres that were markedly bigger
and incorporated more bromodeoxyuridine (BrdU), effects that
were not due to a survival effect as no changes in the number of
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apoptotic or necrotic cells were observed after treatment
(Supplementary Fig. 6a–c). In contrast, neurospheres isolated
from the SGZ expressed endogenous IGF2 and did not respond to
the addition of recombinant IGF2 protein to the cultures
(Supplementary Fig. 6c,d). Furthermore, we detected IGF2 by
enzyme-linked immunosorbent assay (ELISA) in conditioned
media of primary neurospheres acutely isolated from adult SGZ
but detected none in the conditioned medium of SVZ primary
neurospheres, supporting the hypothesis that NSCs from the SGZ
produce endogenous IGF2 (Fig. 3b).
To determine the capacity of NSCs to respond to endothelial-
produced IGF2 in vivo, we co-cultured wild-type adult NSCs with
primary CP epithelial cells (CP) or brain endothelial cells (BECs)
acutely isolated from 1-month-old wild-type mice (Fig. 3c–f)41,42.
These co-cultures induced a signiﬁcant increase in SVZ
neurosphere formation that was partially abrogated by the
addition of IGF2-blocking antibody (Fig. 3f). No effects were
observed in NSCs derived from the SGZ (Fig. 3f). Consistent with
this, similar co-culture experiments of wild-type NSCs with Igf2
mutant-derived CP epithelial cells or BECs, known to express
reduced levels of Igf2 (Fig. 3g), showed a reduced response in SVZ
neurosphere formation compared with wild-type co-cultures
(Fig. 3h), supporting the dose-sensitive role of endothelial-
produced IGF2 in SVZ-NSCs self-renewal. These data together
suggest that IGF2 acts as a niche-secreted NSC paracrine
regulator and that the absence of Igf2 imprinting is necessary in
the SVZ throughout the life course, whereas no paracrine effects
for IGF2 were observed in the SGZ neurospheres.
To further test whether brain endothelial IGF2, a previously
undescribed source of IGF2, regulates NSC behaviour in vivo,
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Figure 2 | Biallelic and monoallelic expression of Igf2 regulate SVZ versus SGZ adult neurogenesis. (a) Schematic drawing of the CldU injection
protocol. (b) Quantiﬁcation of the total number of CldU-label-retaining cells (LRCs) that are GFAPþ/Nestinþ in the SVZ of Igf2þ /þ , Igf2þ /pat, Igf2mat/þ
and Igf2mat/pat mice. (c) Quantiﬁcation of the percentage of LRC/GFAP/Ki67þ cells in the SVZ of Igf2 mutant mice (left panel). Fewer activated cells are
observed in the absence of Igf2. High-magniﬁcation images of triple-positive LRC (red), GFAP (blue) and Ki67 (green) cells in wild-type and Igf2-deﬁcient
SVZ (right panel). (d) Quantiﬁcation of the total number of GFAPþ NSCs contacting the ventricle in a pinwheel organization within the SVZ of the
different Igf2 mutant mice. (e) Whole-mount preparations of the SVZ wall immunostained for g-tubulin (red), b-catenin (blue) and GFAP (green) in Igf2
mutant mice. Arrowheads indicate the ventricle contacting g-tubulinþ cilia of GFAPþ NSC cells (sagittal plane). (f) Quantiﬁcation of the number of LRC
reaching the granular (grl) or periglomerular (pgl) layers in the olfactory bulb (OB) of Igf2þ /þ , Igf2mat/þ , Igf2þ /pat and Igf2mat/pat mice.
(g) Quantiﬁcation of the total number of LRCs that are GFAPþ/SOX2þ in the dentate gyrus of Igf2þ /þ , Igf2mat/þ and Igf2þ /pat heterozygotes and
homozygous knockout Igf2mat/pat mice. Maternal transmission of the mutation has no effect indicative of its imprinted repression on the maternal allele.
(h) Quantiﬁcation of the percentage of GFAPþ cells that also express Ki67 and the DCXþ cells in the hippocampus of the different Igf2 mutant mice.
(i) Quantiﬁcation of the total number of newborn LRC–NeuNþ neurons in the SGZ of the hippocampus of Igf2 mutant mice, showing a defect in the total
neurogenesis only following paternal transmission of the mutation. 4,6-diamidino-2-phenylindole was used to counterstain nuclei. One-way analysis of
variance and Tukey’s post-test. P values and number of animals analysed per genotype are indicated. All error bars show s.e.m. Scale bars, 7 mm (c);
10mm (e).
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we performed a conditional mutagenesis experiment in which
we crossed mice carrying loxP sites ﬂanking the Igf2 gene on
the maternal (Igf2ﬂox/þ ) or paternal (Igf2þ /ﬂox) allele43 with
mice expressing Cre-recombinase under the control of the
endothelium-speciﬁc angiopoietin receptor tyrosine kinase
receptor-2 (Tie2/Tek) promoter (Tie2-creþ /0)44. This resulted
in the reduction of IGF2 expression (both RNA and protein)
in CD31þ endothelial cells of blood vessels in the striatal side
of Igf2ﬂox/þ ;Tie2-creþ /0 (referred to as Igf2-Tie2mat) and
Igf2þ /ﬂox;Tie2-creþ /0 (referred to as Igf2-Tie2pat) compared
with Igf2ﬂox/ﬂox;Tie2-cre0/0 (Igf2-Tie2control) mice (Fig. 4a). We
conﬁrmed that the ﬂoxed allele had effectively recombined in
endothelia by performing X-gal histochemistry in the adult brain
of ROSA26R;Tie2-creþ /0 mice (Fig. 4b). We next examined the
role of endothelial IGF2 in the regulation of NSC maintenance
and proliferation in the two neurogenic niches. The number
of primary neurospheres obtained ex vivo from the SVZ of
Igf2-Tie2mat and Igf2-Tie2pat animals was reduced, whereas no
changes in the hippocampal neurosphere number were found
(Fig. 4c). To directly test whether these effects on SVZ
neurogenesis were due to a reduction in the paracrine IGF2
produced and secreted by blood vessels within the niche, we grew
monolayers of BECs from the Igf2-Tie2mat and Igf2-Tie2pat mice
and co-cultured them with wild-type neurospheres. As described
before, co-cultures with wild-type BECs increased the
neurosphere formation rate. However, this increase was not
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observed in co-cultures with either Igf2-Tie2mat or Igf2-Tie2pat
BECs (Fig. 4d). Finally, 2-month-old mice were injected with the
nucleotide analogue BrdU 3 weeks before killing. We quantiﬁed
the total number of BrdU-LRC/GFAP-positive cells and found a
reduction in the SVZ, whereas no changes were observed in the
adult hippocampus in vivo (Fig. 4e). This reduction in the SVZ
stem cell population was associated with reduced proliferation of
the NSC pool, as fewer GFAP/LRC that were Ki67þ were found
(Fig. 4f). As a result, the number of postmitotic BrdUþ newly
formed neurons in the granular and periglomerular cell layers of
the Igf2-Tie2pat OB was decreased (Fig. 4g). No changes in the
number of new neurons incorporated into the SGZ were observed
(Supplementary Fig. 7). This conﬁrms that endothelial-derived
IGF2 regulates NSC maintenance in SVZ but not SGZ
neurogenesis, and that this is regulated by the biallelic
expression of IGF2 in the vascular compartment.
Monoallelic and biallelic Igf2 act via IGF1R activation. We
sought to characterize the downstream pathways responding to
the differential regulation of Igf2 expression in the two neuro-
genic niches. Consistent with a paracrine and not autocrine role
for IGF2 in the SVZ, neurospheres isolated from homozygous
Igf2 mutant SVZ displayed a similar self-renewal capacity to wild
type upon culture with exogenous IGF2. However, in the absence
of endogenous expression of Igf2, mutant SGZ NSCs responded
to treatment with recombinant IGF2 (Fig. 5a), perhaps suggesting
that the unresponsiveness observed in the hippocampus-derived
NSCs might be caused by a saturation of the IGF2 signalling
pathways in the wild-type cultures. IGF2 can also function as a
survival factor; hence, to determine the potential role of IGF2 in
NSC survival, we quantiﬁed the number of apoptotic bodies in
the wild-type and Igf2 mutant neurosphere cultures in the pre-
sence or absence of recombinant IGF2. Notably, no changes were
observed in SVZ NSCs, but an increase in the percentage of
apoptosis was observed in SGZ-NSCs Igf2mat/pat cultures. This
effect was rescued by addition of exogenous IGF2 (Fig. 5b),
supporting a different role for IGF2 in the two neurogenic niches:
a mitogenic paracrine in the SVZ and an autocrine role as a
survival factor in the SGZ.
The IGF system consists of two ligands and multiple signalling
receptors with different downstream effectors. More speciﬁcally,
IGF2 binds with high afﬁnity to IR-A, IGF1R and to the hybrid
receptor and can interact with IGF2R to target the ligand to
lysosomes for degradation18,19. At the messenger RNA level,
IR-A, IR-B, IGF1R and IGF2R have similar expression in the SVZ
and SGZ niches, with IR-A and IGF1R being the most strongly
expressed receptors (Supplementary Fig. 8a). Consistent with this,
GFAPþ cells in the SVZ and SGZ expressed both IR and IGF1R
proteins (Fig. 5c,d). Treatment of SVZ-derived neurospheres with
20 ngml 1 of recombinant IGF2 increased phospho-IR and
phospho-IGF1R levels, whereas no effect was observed on
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SGZ-derived neurospheres (Fig. 5e; Supplementary Fig. 8b). No
changes on IGF2R were observed in either case. These data
suggest that paracrine IGF2 is taken up by the SVZ NSCs via
activation of IR and/or IGF1R. To further study the potential
function of IGF1R in NSC biology, we performed an
immunoprecipitation using an IGF1R antibody followed by
immunoblotting for the presence of the ligand in NSCs from
SVZ and SGZ. Neurospheres were cultured in the absence or
presence of recombinant IGF2. In the absence of IGF2, SVZ NSCs
do not show binding of IGF2 to the IGF1R, whereas binding to
the receptor was clearly observed after IGF2 treatment (Fig. 5f).
Importantly, in SGZ NSCs the ligand appears bound to the
IGF1R before IGF2 treatment, indicating an interaction between
endogenous IGF2 and the receptor and suggesting that ligand-
binding sites on the receptor are already occupied by autocrine
IGF2 (Fig. 5f). Hence, despite the demonstrable presence of the
IGF1R in wild-type SGZ-derived neurospheres, exogenous IGF2
has no effect on either neurosphere growth or intracellular
signalling, consistent with saturation of the signalling pathways
by autocrine production of IGF2 in the wild-type SGZ. To
determine whether the IGF1R was required for the effects of IGF2
on neurosphere formation, we performed a receptor inhibition
experiment using IGF1R antibodies in the neurosphere formation
assay. In the SVZ NSCs, treatment with IGF2 promoted
neurosphere formation and blocking IGF1R binding impaired
this in both wild-type and Igf2 mutants. The promotion of SGZ
sphere formation by exogenous IGF2 in Igf2-deﬁcient NSCs was
also mediated by IGF1R binding (Fig. 5g). This suggests that in
both neurogenic niches, IGF2 acts primarily via the IGF1R to
promote postnatal neurogenesis.
It has previously been shown that IGF2 acts via AKT to
regulate NSC proliferation24. To determine whether this
molecular mechanism underlies the differential action of IGF2
on NSCs within the two niches, we analysed the role of
AKT-dependent signalling after acute knockdown of Igf2 in
neurospheres derived both from the SVZ and the SGZ with a
lentivirus expressing a silencing short hairpin RNA (shRNA)
directed against Igf2 messenger RNA (Supplementary Fig. 8c).
Although no changes in phospho-AKT (pAKT) were observed
after Igf2 knockdown in SVZ-derived neurospheres, addition of
exogenous IGF2 did increase pAKT levels in these cells
(Supplementary Fig. 8d), supporting the paracrine role of IGF2
in the SVZ NSCs. shRNA-mediated knockdown of Igf2 also led to
a reduction in pAKT levels in hippocampal NSCs (Supplementary
Fig. 8d), supporting the survival effect of IGF2 in the SGZ NSCs.
In conclusion, IGF2 functions in a paracrine and autocrine
manner in the SVZ and SGZ, respectively, mediated by speciﬁc
activation of IGF1R and subsequent induction of the pAkt
downstream pathway.
Discussion
This study shows that biallelic versus monoallelic expression of
Igf2 in the adult brain is functionally and speciﬁcally important
in vivo. We demonstrate that the physiological temporal and
region-speciﬁc modulation of Igf2 imprinting plays a key role in
regulating NSCs in the adult SVZ and SGZ neurogenic niches. In
the majority of tissues, particularly during fetal development, Igf2
expression occurs solely from the paternal allele23,33,34. The key
ﬁndings of our study are that functionally important Igf2 is not
only expressed from the paternally inherited allele but also from
the maternally inherited allele in the vasculature, CP, meninges
and leptomeninges of the adult brain, and such biallelic
expression is required to support SVZ neurogenesis. In vitro
explant models have shown that IGF2 from the embryonic CSF
inﬂuences the proliferation of cortical progenitors14. Our results
signiﬁcantly extend these ﬁndings, showing that Igf2 deﬁciency
in vivo impairs the activation of the adult stem cell pool in the
SVZ under physiological conditions, most likely due to the lower
concentration of IGF2 secreted by the vasculature and the CP.
Using the conditional deletion of Igf2 from the brain vascular
compartment, we demonstrate the previously unrecognized
functional importance of the endothelium compartment as a
source of paracrine IGF2 in SVZ neurogenesis. In contrast, we
show that SGZ NSCs rely on canonically imprinted autocrine
IGF2 expressed only from the paternal allele.
Previous studies showed that shRNA-mediated knockdown of
Igf2 speciﬁcally in adult mouse DG and SVZ led to reduced NSC
proliferation in the DG, but had no effect on SVZ-NSCs24. Our
ﬁndings explain this observation and illustrate the sophisticated
regulation of IGF2 dosage through imprinting modulation in the
two neurogenic compartments. We propose a model in which
monoallelic Igf2 expression is sufﬁcient to maintain IGF2
concentration at the site of action in autocrine SGZ signalling.
In contrast, we suggest that paracrine signalling via the CSF and
endothelial compartment requires biallelic Igf2 expression to
maintain a sufﬁciently high concentration of IGF2 at the target
NSCs following diffusion within the SVZ (Supplementary
Fig. 10). We demonstrate that IGF2 acts via the IGF1R in both
neurogenic niches, but that in the wild-type SGZ this signalling
pathway is saturated by autocrine IGF2, rendering it unresponsive
to exogenous or vascular-derived IGF2 both in vivo and in vitro.
In addition, we show that IGF2 acts as a self-renewal promoting
molecule in the SVZ, whereas in the SGZ the autocrine IGF2
prevents NSCs from apoptosis.
The role of genomic imprinting in gene dosage control is not
fully understood. It is interesting to consider whether biallelic
expression evolved from the imprinted state, or represents
preservation of an ancestral mode of regulation maintained
because the mitogen demand in the SVZ renders the evolutionary
cost of functional haploidy too high in these tissues. It is possible
that imprinted expression in the SGZ represents an evolved
mechanism to limit IGF2 dosage as a means to prevent
overstimulation of the autocrine signalling axis. Regulation of
adult neurogenesis through the selective absence of IGF2
imprinting is reminiscent of recent work showing that selective
biallelic expression of another imprinted gene, Dlk1, is required
for adult neurogenesis38. Together these ﬁndings suggest
that genomic imprinting can be used as a mechanism of gene
dosage control in particular developmental contexts and raises
questions about the evolution, adaptability and ﬂexibility of
imprinting as an epigenetically regulated process that can
respond to intrinsic environmental cues. Further studies will
determine whether non-cerebral stem cell niches can also
modulate genomic imprinting, and will investigate the
signalling processes and epigenetic mechanisms underlying
imprinting dynamics.
Methods
Animals and in vivo manipulations. The generation of Igf2 mutant mice has been
described previously39. Mice were maintained on a C57BL6 background and
crossed with CD1 to generate viable adult offspring of wild-type (Igf2þ /þ ),
maternal (Igf2mat/þ ) and paternal (Igf2þ /pat) transmission heterozygotes and
homozygous null Igf2mat/pat mutant mice. Igf2 mutant animals were genotyped by
PCR analysis of DNA, extracted from mouse ear-punch tissue with the following
primers: Igf2-E6F (50-TGGCCTGGTATCCAAAACAT-30), Igf2-E6R (50-CTGGAT
GACATGGACAGTGG-30) and Neo-E6F (50-AGCGCATCGCCTTCTATC-30).
Tie2-creþ /0(B6.Cg-Tg (Tek-cre)1Ywa/J) mice were obtained from The Jackson
Laboratory. Igf2;Tie2-cre ﬂoxed mice were generated as described previously43, and
genotypes were determined with the following primers: for the deletion, II-delF
(50-TTACAGTTCAAAGCCACCACG-30), II-delRW (50-GCCAAAGAGATGA
GAAGCACC-30) and II-delRD (50-GCCAAACACAGTAAAAAGAAATGC-30).
For the transgene, oIMR1084F (50-GCGGTCTGGCAGTAAAAACTATC-30) and
oIMR1085R (50´-GTGAAACAGCATTGCTGTCACTT-30). Internal control,
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oIMR7338F (50-CTAGGCCACAGAATTGAAAGATCT-30) and oIMR7339R
(50-GTAGGTGGAAATTCTAGCATCATCC-30). See also ‘Imprinting assay’
below. Housing of mice and all experiments were carried out in accordance with
UK and Spanish Government Home Ofﬁce licensing procedures.
Immunostaining and b-galactosidase histochemistry. Thymidine analogues
administration regimes have been previously detailed38,40. Brieﬂy: mice at 2–4
months of age were injected intraperitoneally with 50mg of 5-chloro-20-
deoxyuridine (Sigma) or BrdU (Sigma) per kg of body weight every 2 h for 12
consecutive hours (7 injections in total). At 30 days after the injections, animals
were deeply anaesthetized and transcardially perfused with 4% paraformaldehyde
(PFA) in 0.1M phosphate buffer pH 7.4 (PB) and brains were vibratome-sectioned
at 40mm. For immunohistochemistry, sections were washed in PBS and blocked at
room temperature for 1 h in PBS (0.9% NaCl in PB) with 0.1% Triton X-100
supplemented with 10% FBS and then incubated overnight at 4 C with primary
antibodies (Supplementary Table 1). For CldU or BrdU detection, sections were
pre-incubated in 2N HCl for 30min at 37 C and neutralized in 0.1M sodium
borate (pH 8.5). For BrdU incorporation analysis in vitro, neurospheres cultured
for 48 h in complete medium were treated with 2 mM of BrdU for 10min and
seeded onto poly-L-lysine-coated glass coverslips and ﬁxed with 4% PFA for
20min The coverslips were then treated with 2N HCl for 15min, neutralized in
0.1M borate buffer (pH 8.5) and incubated for 90min at 37 C with rat anti-BrdU
antibody (1:500; Abcam) in blocking buffer. Secondary antibodies (Supplementary
Table 2) were incubated in blocking buffer for 1 h. Nuclei were counterstained with
1mgml 1 of 4,6-diamidino-2-phenylindole. For IGF2 staining, Igf2 knockout SVZ
sections were used to conﬁrm antibody speciﬁcity. For SVZ whole mounts, we used
protocols established previously45. Brieﬂy, the lateral walls of the LV were dissected
out and the resulting whole mounts were ﬁxed for 1.5 h in 4% PFA and washed
overnight at 4 C in PB. Whole mounts were washed three times in PB containing
2% Triton X-100 for 15min each, blocked for 2 h in 10% FBS and 2% Triton X-100
in PB, then incubated for 48 h at 4 C with primary antibodies in the same blocking
solution. After incubation with appropriate secondary antibodies, the stained walls
were mounted with Fluorsave (Calbiochem) between two coverslips. 4,6-
diamidino-2-phenylindole (1mgml 1, 5min) was used for counterstaining.
Samples were analysed using an Olympus FV100 confocal microscopes. For X-gal
histochemistry, brains were ﬁxed by immersion in 4% PFA in PBS at pH 7.4 with
2mM MgSO4 and 5mM EGTA for 30min at 4 C and processed for vibratome
sectioning. Sections were incubated in PBS with 2mM MgCl2, 5mM K3Fe(CN)6,
5mM K4Fe(CN)6, 0.01% sodium deoxycholate and 0.02% NP-40 and 1mgml 1
X-Gal for 24 h and counterstained with nuclear Fast Red.
Gene expression studies. RNA was extracted with Trizol (Invitrogen),
following the manufacturer’s guidelines. For quantitative PCR, 1 mg of total RNA
was DNase-treated with RQ1 RNase-free DNase (Promega), following the
manufacturer’s instructions. All complementary DNAs (cDNAs) were
synthesized using random primers and SuperScript II RT reverse transcriptase
(Invitrogen), following standard procedures. cDNA samples were diluted
1:10 and reactions were performed using Taqman Probes (Supplementary Table 3)
in a Step One Plus cycler with Taqman Fast Advanced Master Mix (Applied
Biosystems).
Imprinting assay. Igf2 imprinting assays were based on PCR ampliﬁcation
followed by direct sequencing to analyse parental-allele-speciﬁc gene expression.
To determine the imprinting status of Igf2 in the CP, we used the reciprocal F1
hybrid offspring of Mus musculus domesticus (strain C57BL/6, abbreviated BL6)
and Mus musculus castaneus (strain CAST/EiJ, abbreviated Cast) subspecies, in
which a single-nucleotide polymorphism (SNP) was identiﬁed between the two
subspecies. The sequences of murine Igf2 were obtained from GenBank (accession
number NM_010514). PCR of the hybrid cDNA samples was performed using
primers Igf2SNP-F (50-CACGTCCCACACTAAGATCTCTC-30) and Igf2SNP-R
(50-GGGGTGTCAATTGGGTTGT-30) with the thermal cycler conditions: 94 C
1min, 60 C 1min, 72 C 1min and 30 cycles. The primer Igf2SNP-R was used for
direct reverse PCR fragment sequencing. Genomic DNA sequence traces from BL6
and Cast placentae were used to identify the Igf2 strain-speciﬁc polymorphism that
was a guanine ‘G’ in BL6 mice and an adenine ‘A’ in Cast mice (Supplementary
Fig. 2i) and located on exon 1.
Cell cultures and co-culture experiments. Methods for NSC culture derived
from SVZ and self-renewal assessment40. Brieﬂy, brains were dissected out and the
SVZ isolated in Earle’s balanced salt solution (Invitrogen). Tissues were transferred
to Earle’s balanced salt solution containing 1.0mgml 1 papain (Worthington
DBA), 0.2mgml 1 L-cystein (Sigma), 0.2mgml 1 EDTA (Sigma), incubated for
30min at 37 C and carefully triturated with a ﬁre-polished Pasteur pipette to a
single-cell suspension. Isolated cells were resuspended in DMEM/F12 medium
containing 2mM L-glutamine, 0.6% glucose, 9.6 gml 1 putrescine, 6.3 ngml 1
progesterone, 5.2 ngml 1 sodium selenite, 0.025mgml 1 insulin, 0.1mgml 1
transferrin, 2 mgml 1 heparin (sodium salt, grade II; Sigma) (control medium)
and supplemented with 10 ngml 1 of epidermal growth factor (human
recombinant; Invitrogen) and 20 ngml 1 of basic FGF (FGF2; human
recombinant; Sigma) (complete medium). For each passage, spheres formed after
4–6 days in vitro. For self-renewal assays, neurospheres were treated with Accutase
(0.5mM; Sigma) for 10min, mechanically dissociated to a single-cell suspension
and replated in complete medium. SGZ-derived neurosphere cultures were
obtained by dissecting out DG fragments and digesting in 0.025% trypsin and
0.265mM EDTA (Invitrogen). A single-cell suspension was obtained by gentle
trituration and diluted in complete medium. Neurospheres were allowed to develop
for 6 days in a 95% air–5% CO2-humidiﬁed atmosphere at 37 C. Some cultures
were supplemented with recombinant Mouse IGF2 (50 ngml 1; R&D Systems) or
blocking anti-IGF2, anti-IGF1R and non-relevant antibodies (3 mgml 1; Santa
Cruz). Primary CP epithelial cells were cultured as previously described42. Brieﬂy,
ﬁve neonatal mice aged 7 days postpartum were killed by cervical dislocation,
brains dissected out and CP transferred to a HBSS solution containing 2mgml 1
of Pronase. After 5min incubation at 37 C, choroid plexi were disaggregated by
pipetting to generate a single-cell suspension, plated at 500 cells per millilitre and
incubated overnight at 37 C in 5% CO2/air to allow for cellular attachment. The
medium containing unattached cells and debris was removed and cells were gently
washed twice with PBS. Fresh new medium supplemented with 20 mM AraC was
added to suppress ﬁbroblast proliferation. The medium was changed every 48 h
until the cells became conﬂuent (7–10 days) at which point cultures were used for
neurosphere co-culture assays. Cells were viable for several weeks with correct
maintenance and without signiﬁcant loss of marker gene expression or
morphological features. Primary BECs were also obtained as previously
described41. For co-culture experiments, the feeder CP epithelial or BECs’ media
were replaced by neurosphere growth medium. After 2 h, a transwell insert (0.4mm
pore, 12mm diameter; Millipore) was placed above, and dissociated NSCs were
seeded in the upper compartment at a clonal density of 2.5 cells per microlitre.
Neurosphere formation and diameter were analysed after 5 days incubation at
37 C and 5% CO2.
Enzyme-linked immunosorbent assay (ELISA). The CP epithelial cells, BECs’ or
NSCs media were collected after 4 days of conditioning and the levels of IGF2 were
determined via ELISA following the manufacturer’s guidelines (IGF2 Mouse ELISA
Kit, Abcam). Absorbances were measured using a VICTOR microplate reader
(PerkinElmer) at 450 nm, and the amount of IGF2 was calculated from the
standard curve in the detection limit range.
Igf2 knockdown experiments and immunoblotting. Neurospheres freshly
disaggregated were electroporated with lentiviral vectors carrying an Ig2-speciﬁc
shRNA (TRC Clone number 0000071148, Sigma) or a non-target control (Mission
SHC002, Sigma), using the Amaxa NSC Nucleofector kit and following the
manufacturer instructions. Cells were starved for 6 h by removing growth factors
and insulin 2 days after electroporation. Next, cells were treated with 20 ngml 1 of
IGF2 for 15min. and washed with cold PBS. Cells were then lysed in RIPA buffer.
Total protein concentration was determined using the BCA system (Pierce).
Equal amounts (30 mg) of protein were loaded on polyacrylamide gels for
SDS–polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose
membranes and immunoblots were carried out using primary antibodies
(Supplementary Table 1) followed by incubation with appropriate secondary
horseradish peroxidase-conjugated antibodies (Supplementary Table 2) and
chemoluminiscent detection (Western Lightning, PerkinElmer). For immunopre-
cipitations,B106 cells were split in two and either treated or not with 20 ngml 1
IGF2 for 10min, collected on ice in PBS supplemented with sodium orthovanadate
and lysed in 25mM Tris-HCl, pH 7.4, 150mM NaCl, Triton X-100 1% and 1mM
EDTA supplemented with phosphatase and protease inhibitors. Lysates were
incubated overnight with 3 mg of anti-IGFR1 antibody (1:1,000, Cell Signaling), and
Dynabeads protein G (Invitrogen) were used to retrieve the immunoprecipitates.
Beads were incubated with Laemmli buffer and separated from the samples using a
magnet. Immunoprecipitates were resolved in 10% Criterion TGX Precast Gel
(Bio-Rad) and transferred to nitrocellulose membranes (Protran Sigma).
Membranes were blotted with primary anti-IGF2 and secondary peroxidase-
conjugated antibodies (1:5,000; Bio-Rad) and reacted by chemiluminiscence. All
antibodies were diluted in PBS containing 5% semi-skimmed milk and 0.025%
Tween-20. Autoradiographic ﬁlms were scanned and the bands were analysed by
densitometry using Scion Image software. Uncropped western-blots are shown in
Supplementary Fig. 9.
Statistical analysis. All statistical tests were performed using the GraphPad Prism
Software, version 4.00 for Windows (http://www.graphpad.com). The signiﬁcance
of the differences between groups was evaluated in all experiments by a one-way
analysis of variance followed by a Tukey’s post hoc test. When comparisons were
performed with relative values (normalized values and percentages), data were
normalized using an arcsen transformation. Treatment experiments were analysed
by a paired t-test. Data are presented as the mean±s.e.m., and the number of
experiments performed with independent cultures or animals (n) is indicated in the
legends. The signiﬁcance of the differences is provided: *Po0.05, **Po0.01,
***Po0.001.
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